Mednet's AI Tool, Backed by NCI, Tackles Cancer Trial Enrollment Crisis

NEW YORK, NY – August 20, 2026 – In the high-stakes world of oncology, clinical trials represent the frontier of hope, offering patients access to potentially life-saving treatments while advancing the fight against cancer. Yet, this frontier is often inaccessible. A persistent and frustrating gridlock in patient enrollment means that promising research frequently stalls. Now, a new technology aims to break the impasse not with a new drug, but with intelligent software. Mednet, a large physician-only digital community, has launched TrialMatch, an AI-powered tool designed to slash the time it takes for oncologists to find appropriate clinical trials for their patients from hours to mere minutes.

Developed with a $2 million contract from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program, TrialMatch is more than just another search engine. It's an integrated solution designed to weave trial discovery into the very fabric of a physician's daily workflow, addressing a critical bottleneck that has long hampered medical progress. For the 93% of adult cancer patients who never participate in a clinical trial, this innovation could represent a pivotal shift in their treatment journey.

The Anatomy of a Bottleneck

The challenge of clinical trial enrollment is a well-documented crisis in oncology. According to industry data, approximately one in five trials closes prematurely simply because they cannot recruit enough participants. This not only represents a significant waste of research funding and scientific effort but also delays the arrival of new therapies to the market. The problem isn't a lack of eligible patients; it's a breakdown in the connection between the patients and the trials that could help them.

For frontline oncologists, the process of identifying a suitable trial is a Herculean task. They must navigate a labyrinth of complex eligibility criteria, sifting through databases like ClinicalTrials.gov, which are built primarily for researchers, not for time-pressed clinicians at the point of care. Matching a patient's specific diagnosis, cancer stage, biomarkers, prior therapies, and comorbidities against dozens of potential trials is a manual, time-consuming process that pulls physicians away from direct patient care.

"Finding the right clinical trial shouldn't require physicians to step away from patient care and search through multiple databases," said Nadine Housri, MD, Co-founder and Chief Medical Officer of Mednet, in the company's announcement. The launch of TrialMatch targets this exact pain point, aiming to transform trial discovery from an arduous administrative burden into a streamlined, intelligent part of the clinical decision-making process.

AI in the Workflow: How TrialMatch Works

TrialMatch's innovation lies in its practical application of artificial intelligence directly within the clinical environment. The tool is embedded within Mednet AI, the platform's clinical assistant, which is used by its community of over 45,000 physicians. Instead of structured queries, an oncologist can describe a patient's case in natural language. The AI then parses this information and scours trial databases, matching the profile against a host of factors including diagnosis, biomarkers, location, and even specific lab values or performance status.

The system returns not just a list of trials, but also a clear rationale for why each trial is a potential match, along with direct enrollment links. This transparency allows physicians to quickly evaluate and validate the AI's suggestions. The goal is to deliver actionable intelligence, not just raw data. While Mednet has not released specific accuracy metrics for TrialMatch, similar AI-driven systems in the research phase have demonstrated impressive results, with some achieving over 90% accuracy in classifying trial criteria, suggesting a strong technological foundation for such tools.

Crucially, TrialMatch also operates passively within Mednet's bustling physician community, where thousands of specialists discuss challenging cases. The AI can identify conversations where a patient's profile might fit an enrolling trial and proactively surface that information. This ambient discovery process means opportunities are less likely to be missed, turning peer-to-peer consultation into a potential gateway for trial access.

A Public-Private Blueprint for Innovation

The development of TrialMatch is a testament to the power of strategic collaboration between the public and private sectors. The $2 million NCI SBIR contract not only funded the tool's creation but also underscores the federal government's recognition of the enrollment crisis as a critical barrier to advancing its cancer research objectives.

This partnership extends beyond funding. The contract also supports a prospective evaluation of TrialMatch in collaboration with the SWOG Cancer Research Network, one of the most respected cooperative groups in the NCI's National Clinical Trials Network. SWOG has been instrumental in many of oncology's most practice-changing clinical trials, and its involvement lends significant scientific credibility to the project. The study will rigorously assess whether the AI-assisted tool genuinely increases physician awareness and, most importantly, improves patient enrollment rates. This commitment to evidence-based validation sets TrialMatch apart from many tech solutions that enter the market without formal efficacy studies.

Experts involved in the collaboration see immense potential. Dr. Lajos Pusztai, Chair of the Breast Cancer Committee at SWOG, noted that finding trials is often a "bottleneck for accrual," calling TrialMatch an "innovative online tool to match patients to trials that could save time, and perhaps lives too." This validation from a leading research network highlights the demand for such a solution within the oncology community.

Navigating a Competitive Digital Health Landscape

Mednet is not the first to apply technology to the trial matching problem. The space includes patient-facing platforms like Antidote and Clara Health, as well as sophisticated data-driven services from companies like Tempus, which also uses AI to support trial matching. However, Mednet's strategy contains several distinct advantages that could drive rapid adoption.

First is its massive, built-in user base. By deploying TrialMatch within a community where 45,000 physicians are already active, Mednet bypasses the cold-start problem that plagues many new platforms. The tool is introduced to oncologists in a trusted environment where they already seek clinical guidance.

Second, the "no cost" model for oncologists removes a significant barrier to entry. This approach, likely made sustainable by the NCI funding and Mednet's broader business strategy, prioritizes widespread use and impact. By making the tool freely accessible, Mednet positions TrialMatch as a fundamental utility for modern oncology practice rather than a premium, add-on service.

Ultimately, Mednet's vision appears centered on creating an indispensable ecosystem for physicians, powered by a combination of peer expertise and intelligent tools. By embedding TrialMatch directly into the daily conversations and workflows of thousands of oncologists, the company is not just launching a product; it is re-engineering the process of how patients connect to the cutting edge of cancer care.